Acitretin revisited in the era of biologics

Journal of Dermatological Treatment

Volumn 22, Issue 2, 2011, Pages 86-89

  Booij, Mariëlle Te ^a   Van De Kerkhof, Peter C M ^a  

^a RUN MC ^*  (Netherlands)

Author keywords

acitretin; biologics; psoriasis; therapy

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CALCIPOTRIOL; CYCLOSPORIN; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; PIOGLITAZONE; STEROID RECEPTOR; USTEKINUMAB;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE PAIN; CHILL; CHOLESTEROL BLOOD LEVEL; COLOR VISION; CONJUNCTIVITIS; CONVULSION; DERMATITIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSPEPSIA; DYSPNEA; EDEMA; EOSINOPHILIA; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GUM HYPERPLASIA; HEADACHE; HEPATITIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; IDIOPATHIC INTRACRANIAL HYPERTENSION; INFECTION RISK; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; JAUNDICE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NIGHT VISION; PARESTHESIA; PHOTOSENSITIVITY; PHOTOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RETINOID DERMATITIS; REVIEW; RHINITIS; SIDE EFFECT; SKIN CANCER; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VITAMIN A TOXICITY;

ACITRETIN; DRUG THERAPY, COMBINATION; HUMANS; KERATOLYTIC AGENTS; PSORIASIS;

EID: 79952374791     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903578582     Document Type: Review

References (19)

1. Young HS, Summers AM, Read IR, Fairhust DA, Plant DJ, Campalani E, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126(2): 453-459. (Pubitemid 43323183)
2. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317(5835):256-260. (Pubitemid 47076203)
3. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: A 24-week, randomized, controlled, investigatorblinded pilot trial. Br J Dermatol. 2008;158(6):1345- 1349. (Pubitemid 351692891)
4. Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross JB, Stewart WD, et al. A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter study. J Am Acad Dermatol. 1991;24(4):598-602.
5. Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1): 35-40. (Pubitemid 19028329)
6. Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: Effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008;158(1):116-121. (Pubitemid 350221914)
7. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658-665. (Pubitemid 36975998)
8. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3): 558-566. (Pubitemid 351239154)
9. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJ. Guidelines for biologic interventions for psoriasis. Br J Dermatol. 2009;161:987-1019.
10. Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126(2): 453-459. (Pubitemid 43323183)
11. Caca-Biljanovska NG, V'Lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: Prospective randomized study. Croat Med J. 2002;43(6): 707-712. (Pubitemid 41490286)
12. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003;139(4):436-442. (Pubitemid 36427607)
13. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol. 1989;20(6):1088-1093. (Pubitemid 19151521)
14. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989; 121(1):107-112. (Pubitemid 19177127)
15. Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo- PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177(4):218-224.
16. Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, et al.; for the National Psoriasis Foundation. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009 Jul 29 [Epub ahead of print].
17. Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387-393.
18. Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: Biologics and acitretin for the treatment of psoriasis - A case series. J Dermatolog Treat. 2006;17(2):86-89.
19. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999;41(3 Pt 2):S22-S24 (Pubitemid 29416464)